Availability, prices and affordability of the World Health Organization’s essential medicines for children in Guatemala
Several World Health Organization (WHO) initiatives aim to improve the accessibility of safe and effective medicines for children. A first step in achieving this goal is to obtain a baseline measure of access to essential medicines. The objective of this project was to measure the availability, prices, and affordability of children’s medicines in Guatemala.
An adaption of the standardized methodology developed by the World Health Organization and Health Action International (HAI) was used to conduct a cross sectional survey to collect data on availability and final patient prices of medicines in public and private sector medicine outlets during April and May of 2010.
A subset of the public sector, Programa de Accesibilidad a los Medicamentos (PROAM), had the lowest average availability (25%) compared to the private sector (35%). In the private sector, highest and lowest priced medicines were 22.7 and 10.7 times more expensive than their international reference price comparison. Treatments were generally unaffordable, costing as much as 15 days wages for a course of ceftriaxone.
Analysis of the procurement, supply and distribution of specific medicines is needed to determine reasons for lack of availability. Improvements to accessibility could be made by developing an essential medicines list for children and including these medicines in national purchasing lists.
- World Health Organization: Communicable Disease Cluster: Removing obstacles to healthy development: report on infectious diseases. http://www.who.int/infectious-disease-report/pages/textonly.html
- United Nations Childrens' Fund: The state of the world's children 2008. New York: UNICEF; 2007.
- The United Nations: The millenium development goals report 2010. New York: United Nations; 2010.
- Rajaratnam JK, Marcus JR, Flaxman AD, Wang H, Levin-Rector A, Dwyer L, Costa M, Lopez AD, Murray CJ: Neonatal, postneonatal, childhood, and under-5 mortality for 187 countries, 1970–2010: a systematic analysis of progress towards Millennium Development Goal 4. Lancet 2010,375(9730):1988–2008. CrossRef
- Robertson J, Forte G, Trapsida JM, Hill S: What essential medicines for children are on the shelf? Bull World Health Organ 2009,87(3):231–237. CrossRef
- Overview of methods for medicines availability and pricing surveys: Better Medicines for Children Project. http://www.who.int/childmedicines/progress/ChildMeds_pricing_surveys.pdf
- Health Action International; World Health Organization: Meassuring medicine prices, availability, affordability and price components. http://www.haiweb.org/medicineprices/manual/documents.html
- Pan American Health Organization: Health in the Americas: Guatemala. http://www.paho.org/hia/archivosvol2/paisesing/Guatemala%20English.pdf
- Congreso de la República de Guatemala: Ley de accesibilidad a los medicamentos. 1998, 69–98.
- Congreso de la República de Guatemala: Ley de contrataciones del estado. 1992, 57–92.
- Shaffer ER, Brenner JE: A trade agreement's impact on access to generic drugs. Health Aff (Millwood) 2009,28(5):w957-w968. CrossRef
- Ventas sociales y farmacias privadas: Ministerio de Salud. http://www.mspas.gob.gt/
- Jefatura del departamento de regulación y control de productos farmacéuticos y afines. 2001. http://www.medicamentos.com.gt/index.php/legislacion-vigente/normas-tecnicas?start=40
- Jefatura del departamento de regulación y control de productos farmacéuticos y afines. 2002. http://www.medicamentos.com.gt/index.php/legislacion-vigente/normas-tecnicas?start=40
- Jefatura del departamento de regulación y control de productos farmacéuticos y afines. 2003. http://www.medicamentos.com.gt/index.php/legislacion-vigente/normas-tecnicas?start=40
- Madden JM, Meza E, Ewen M, Laing RO, Stephens P, Ross-Degnan D: Measuring medicine prices in Peru: validation of key aspects of WHO/HAI survey methodology. Rev Panam Salud Publica 2010,27(4):291–299. CrossRef
- World Health Organization: WHO model list of essential medicines for children: 2nd ed. Geneva, Switzerland: WHO; 2009.
- OANDA: http://www.oanda.com/currency/converter/
- Management Sciences for Health: International drug price indicator guide. http://erc.msh.org/mainpage.cfm?file=1.0.htm&&module=DMP&language=English
- Ridge AL, Bero LA, Hill SR: Identifying barriers to the availability and use of Magnesium Sulphate Injection in resource poor countries: a case study in Zambia. BMC Health Serv Res 2010, 10:340. CrossRef
- Priority Medicines for Maternal and Child Health: A Global Survey of National Essential Medicines Lists. [http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0038055]
- Mendis S, Fukino K, Cameron A, Laing R, Filipe A, Khatib O, Leowski J, Ewen M: The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries. Bull World Health Organ 2007,85(4):279–288. CrossRef
- van Mourik MS, Cameron A, Ewen M, Laing RO: Availability, price and affordability of cardiovascular medicines: a comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord 2010, 10:25. CrossRef
- Cameron A, Roubos I, Ewen M, Mantel-Teeuwisse AK, Leufkens HG, Laing RO: Differences in the availability of medicines for chronic and acute conditions in the public and private sectors of developing countries. Bull World Health Organ 2011,89(6):412–421. CrossRef
- Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R: Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet 2009,373(9659):240–249. CrossRef
- Gwatkin DR, Rutstein S, Johnson K, Suliman E, Wagstaff A, Amouzou A: Socio-economic differences in health, nutrition, and population within developing countries: an overview. Niger J Clin Pract 2007,10(4):272–282.
- Strand TA, Chandyo RK, Bahl R, Sharma PR, Adhikari RK, Bhandari N, Ulvik RJ, Molbak K, Bhan MK, Sommerfelt H: Effectiveness and efficacy of zinc for the treatment of acute diarrhea in young children. Pediatrics 2002,109(5):898–903. CrossRef
- Goel P, Ross-Degnan D, Berman P, Soumerai S: Retail pharmacies in developing countries: a behavior and intervention framework. Soc Sci Med 1996,42(8):1155–1161. CrossRef
- Worldbank: Data by country. http://data.worldbank.org/country/guatemala
- Niens LM, Cameron A, Van de Poel E, Ewen M, Brouwer WB, Laing R: Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing world. PLoS Med 2010,7(8):e1000333. CrossRef
- World Health Organization: WHO model formulary for children. Geneva, Switzerland: World Health Organization; 2010. http://www.who.int/selection_medicines/list/WMFc_2010.pdf
- World Health Organization: Child growth standards. 2011. http://www.who.int/childgrowth/standards/weight_for_age/en/index.html
- Availability, prices and affordability of the World Health Organization’s essential medicines for children in Guatemala
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Globalization and Health
- Online Date
- July 2012
- Online ISSN
- BioMed Central
- Additional Links
- Essential medicines for children
- National formulary
- World Health Organization
- Author Affiliations
- 1. Department of Clinical Pharmacy, University of California, San Francisco, CA, 94143-0622, USA
- 2. La Universidad del Valle de Guatemala, Vista Hermosa III, Guatemala City, Guatemala, 01015
- 3. Cedar Associates, Menlo Park, CA, 94025, USA
- 4. Department of Clinical Pharmacy, Institute for Health Policy Studies, University of California, San Francisco, CA, 94118, USA